$INMB News
Last published 6d ago
- 6d agoINMBINmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business UpdateGlobeNewswireCompany Advances Ebstrocel™ Toward Potential UK Approval Company to Host Conference Call on November 5, 2026, at 4:30pm ET BOCA RATON, Fla., Nov. 05, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the
- 1w agoINMBINmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5thGlobeNewswireManagement to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, Oct. 29, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company
- 2w agoINMBINmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private PlacementGlobeNewswireBOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has
- 3w agoINMBINmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027GlobeNewswireFinal pre-MAA package submitted to MHRA on October 20, 2026Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by approximately six weeksU.S. BLA
- 3w agoINMBINmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with UnipharGlobeNewswireInitial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc.
- 4w agoINMBQUBTINmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™GlobeNewswireCollaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XProInitial engagement marks QCi's
- 4w agoQUBTINMBINmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™PR NewswireCollaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XProInitial engagement marks QCi's
- 1mo agoINMBINmune Bio to Attend the 2026 Maxim Growth SummitGlobeNewswireBOCA RATON, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, is excited to announce its
- 1mo agoINMBINmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to BoardGlobeNewswireAppointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) --
- 2mo agoINMBINmune Bio to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireThe on-demand presentation will be available on September 11, 2026, at 7:00 A.M. (ET) BOCA RATON, Fla, Sept. 09, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage
- 2mo agoINMBINmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory FilingsGlobeNewswireOrphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEBFilings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained through approval, may
- 3mo agoINMBINmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical ProgressGlobeNewswireBOCA RATON, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced its financial
- 3mo agoINMBINmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6thGlobeNewswireManagement to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company
- 3mo agoINMBINmune Bio Receives R&D Rebates of Approximately $4.6 MillionGlobeNewswireBOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30,
- 3mo agoINMBINmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ PlatformGlobeNewswireGlobal Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product Opportunities BOCA RATON, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- INmune
- 3mo agoINMBINmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ PlatformGlobeNewswireCommercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply. Company Expresses Support for MHRA Draft Rare Disease Therapies
- 3mo agoINMBINmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical StudyGlobeNewswireThe study points to soluble TNF as a key biological link between head injury and Alzheimer’s disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloid pathology while
- 4mo agoINMBINmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAICGlobeNewswireAdvanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition. White matter
- 4mo agoINMBINmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written OpinionGlobeNewswireSecures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program Ebstrocel for Epidermolysis Bullosa and Next-Generation Engineered Modalities Extending to 2045 BOCA RATON, Fla.,
- 4mo agoINMBINmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™GlobeNewswireApproval of pediatric strategy validates clinical data package and accelerates the regulatory path for CORDStrom™ in the United Kingdom BOCA RATON, Fla, June 25, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc.
- 4mo agoINMBINmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEBGlobeNewswireMHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions covering CMC, non-clinical and clinical evidence packages MHRA pediatric feedback recognizes MissionEB Phase 2 data as
- 5mo agoINMBINmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's TrialGlobeNewswireXPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect. Efficacy was
- 5mo agoGTBPFATENKTXIBRX+1Three TriKE Candidates In Clinic As NK Cell Engager Field ReorganizesPR NewswireThe case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's first ...
- 6mo agoINMBINmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ PlatformGlobeNewswireBoca Raton, FL, May 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB), a clinical-stage biotechnology company developing therapies that target innate immune dysfunction, today announced that results from its
- 6mo agoINMBINmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's DiseaseGlobeNewswireBOCA RATON, FL, May 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced that the U.S. Food and Drug Administration
- 6mo agoINMBINmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection PointGlobeNewswireAlliance launches with 26 founding companies to develop a national strategy for U.S. biotechnology leadership BOCA RATON, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- INmune Bio, a clinical-stage biotechnology company
- 6mo agoINMBINmune Bio Inc. Announces First Quarter 2026 Results and Provides Business UpdateGlobeNewswireBOCA RATON, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to
- 6mo agoINMBINmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory DiseasesGlobeNewswireLONDON, UK and BOCA RATON, FL, May 05, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) ("INmune Bio"), a clinical-stage biotechnology company, and Anthony Nolan, a pioneering UK-based charity that set up the
- 6mo agoINMBBiotech Leaders Launch National Alliance to Define the Future of American InnovationBusiness WireNew coalition forms to develop a national innovation roadmap to strengthen and extend America's global leadership in biotechnology The American Biotech Innovation Alliance (ABIA) today announced its launch, bringing
- 6mo agoINMBINmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7thGlobeNewswireManagement to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and
- 6mo agoINMBINmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer ModelsGlobeNewswireBOCA RATON, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage biotechnology company focused on developing therapies that harness the patient's innate immune
- 7mo agoINMBINmune Bio Inc. Announces 2025 Results and Provides Business UpdateGlobeNewswireBOCA RATON, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announces its financial results for
- 7mo agoINMBINmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.GlobeNewswireManagement to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 24, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and
- 8mo agoINMBINmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's WebinarGlobeNewswireBoca Raton, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) ("INmune" or the "Company"), a late-stage biotechnology company focused on inflammation and immunology, will host a webinar focused on
- 8mo agoINMBINmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEBGlobeNewswireClinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB clinical study Boca Raton, FL, Feb. 19, 2026 (GLOBE NEWSWIRE) --
- 9mo agoINMBINmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer's DiseaseGlobeNewswireAgency Feedback Provides Regulatory Clarity on Enrichment Strategy and Confirms CDR-SB as Sole Primary Endpoint for Registrational Development Boca Raton, FL, Feb. 12, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc.
- 9mo agoINMBINmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEBGlobeNewswirePre-submission package is a process that facilitates early feedback from the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA), designed to streamline the final approval process and reduce
- 9mo agoINMBINmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic InitiativesGlobeNewswireBoca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO: Dear Fellow
- 11mo agoINMBPeer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom™ PlatformGlobeNewswireBoca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB) ("INmune" or the "Company"), a clinical-stage inflammation and immunology company, announces a recently published overview of future
- 11mo agoINMBINmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's PatientsGlobeNewswireBoca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfunction, announces
- 11mo agoINMBINmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD ConferenceGlobeNewswireBoca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical Trials on
- 1y agoINMBINmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business UpdateGlobeNewswireBOCA RATON, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate
- 1y agoINMBINmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025GlobeNewswireManagement to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 23, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), INmune Bio Inc. (NASDAQ:INMB), a
- 1y agoINMBINmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025GlobeNewswireBoca Raton, FL, Oct. 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB), a clinical-stage inflammation and immunology company, today announces that David Moss, Chief Executive Officer will participate in a
- 1y agoINMBINmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer's Disease to npj Dementia, a Nature Portfolio JournalGlobeNewswireBoca Raton, FL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc.
- 1y agoINMBINmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT CatapultGlobeNewswireBOCA RATON, Fla., Sept. 15, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) ("INmune" or "the Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the
- 1y agoINMBINmune Bio, Inc. (INMB) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoINMBINmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management ChangesGlobeNewswireBOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to
- 1y agoINMBINmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to EnrollmentGlobeNewswireBOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial (the "CaRe
- 1y agoINMBINmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7thGlobeNewswireManagement to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and